Galena Biopharma, Inc. s in-depth stock price analysis indicates that the stock price has dropped -79.24% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -91.15% . Looking at the past 52 week period, the stock price is down -95.23% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Galena Biopharma, Inc. has a negative value of -92.87 compared to overall market performance. Galena Biopharma, Inc. (NASDAQ:GALE) has tumbled 38.05% during the past week and has dropped 61.08% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 38.55%. Galena Biopharma, Inc. (NASDAQ:GALE) has underperformed the index by 61.78% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Galena Biopharma, Inc. (NASDAQ:GALE) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0782 points or 9.52% at $0.7434 with 4,187,693 shares getting traded. Post opening the session at $0.7921, the shares hit an intraday low of $0.72 and an intraday high of $0.8042 and the price was in this range throughout the day. The company has a market cap of $14 million and the number of outstanding shares has been calculated to be 18,828,222 shares. The 52-week high of Galena Biopharma, Inc. (NASDAQ:GALE) is $49.802 and the 52-week low is $0.72.
Galena Biopharma Inc Last issued its quarterly earnings results on Aug 9, 2016. The company reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.11. Analyst had a consensus of $-0.06.During the same quarter in the previous year, the company posted $-0.10 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Galena Biopharma Inc was Downgraded by FBR & Co. on Feb 6, 2017 to Mkt Perform, Lowers Price Target to $ 4 from a previous price target of $11 .Galena Biopharma Inc was Downgraded by Maxim Group to Hold on Feb 2, 2017. Company shares were Reiterated by Maxim Group on Dec 2, 2016 to Buy, Raises Price Target to $ 4 from a previous price target of $1 .
Company has reported several Insider transactions to the SEC, on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at 2.18 per share price.
Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon.